Ticker: KRYS

Compañia: Krystal Biotech Inc

Índice: NMS

Sector: Salud

Divisa: EURUSD

Valor actual: 57.06

Descripción:

Noticias de  KRYS

Krystal Biotech, Inc., una empresa de biotecnología en fase clínica, se dedica al campo de la terapia génica redosificable para tratar enfermedades raras graves en los Estados Unidos. Su principal producto candidato es beremagene geperpavec (B-VEC), que se encuentra en un estudio clínico de fase III para tratar la epidermólisis ampollosa distrófica. La empresa también participa en el desarrollo de KB105, que se encuentra en un estudio clínico de fase I / II para el tratamiento de pacientes con ictiosis congénita autosómica recesiva deficiente; KB301, que se encuentra en la etapa clínica de Fase I / II para el tratamiento de arrugas y cicatrices de acné; KB407 que se encuentra en etapa preclínica para fibrosis quística; y KB104, que se encuentra en etapa preclínica para el síndrome de Netherton. Sus candidatos a productos en etapa de descubrimiento incluyen KB5xx para el tratamiento de enfermedades crónicas de la piel, KB3xx para tratar afecciones estéticas de la piel y KB3xx para otras enfermedades pulmonares raras. Krystal Biotech, Inc. fue fundada en 2015 y tiene su sede en Pittsburgh, Pensilvania.

Noticias:

Noticias de  KRYS

Wall Street apunta a un Cyber Monday marcado por las compras médicas

Estrategias de Inversión | Estrategias de Inversión

Noticias de  KRYS

Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Bank of America

Bank of America initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a report released on Tuesday morning, Analyst Ratings Network reports.

ETF Daily News | ETF Daily News

Noticias de  KRYS

Krystal Biotech (NASDAQ:KRYS) Coverage Initiated by Analysts at Bank of America

Bank of America initiated coverage on shares of Krystal Biotech in a research report on Tuesday. They issued a "buy" rating on the stock.

MarketBeat | MarketBeat

Noticias de  KRYS

-$0.77 EPS Expected for Krystal Biotech, Inc. (NASDAQ:KRYS) This Quarter

Wall Street analysts predict that Krystal Biotech, Inc. (NASDAQ:KRYS) will post earnings of ($0.77) per share for the current fiscal quarter, Zacks reports.

MarketBeat | MarketBeat

Noticias de  KRYS

KrystalBiotech Shows Rising Price Performance With Jump To 84 RS Rating

When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is KrystalBiotech...

Investor's Business Daily | Investor's Business Daily

Noticias de  KRYS

Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus rating of "Buy" by the six analysts that are covering the firm, Marketbeat Ratings...

MarketBeat | MarketBeat

Noticias de  KRYS

Could This Soaring Biotech Stock Make You Rich?

Krystal Biotech recently released positive data from a clinical trial for its leading pipeline candidate, Vyjuvek. Vyjuvek could go on to earn regulatory...

The Motley Fool | The Motley Fool

Noticias de  KRYS

Krystal Biotech: Healing 'Butterfly Children' One Topical, Re-Dosable Gene Therapy At A Time

Krystal Biotech's p3 DEB efficacy data seems stronger and more conclusive. Read to know why I think KRYS stock is a solid BUY for investors with suitable...

Seeking Alpha | Seeking Alpha

Noticias de  KRYS

Why Krystal Biotech's Shares Rose More Than 77% This Week

The stock reached its 52-week high on Monday. Krystal Biotech stock dropped a bit on Tuesday when the company announced a stock sale.

The Motley Fool | The Motley Fool

Noticias de  KRYS

Why Krystal Biotech Stock Is Retreating Today

Shares of the gene therapy specialist Krystal Biotech (NASDAQ:KRYS) are down by 13.6% as of 1:38 p.m ET Wednesday afternoon. The biotech's shares are...

The Motley Fool | The Motley Fool

Noticias de  KRYS

TG Therapeutics, Krystal Biotech, BioXcel Therapeutics among major healthcare premarket losers' pack

Aditxt ADTX -21% after launches stock and warrant offering.BioXcel Therapeutics BTAI -19% after FDA extended PDUFA date for BXCL501.

Seeking Alpha | Seeking Alpha